1
Total investments
1
Early stage
0
Mid stage
0
Late stage
4y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor / Board Observer
2022
Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.
Experience · 2 entries
All (2)
Investments (1)
Board (1)
2022
Investor / Board Observer
2022
Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.
2019
General Partner
2019
GV supports innovative founders across multiple stages and sectors, from artificial intelligence and life sciences to consumer platforms, enterprise software, and frontier technology.
Launched as Google Ventures in 2009, GV oversees more than $10 billion in assets under management. Our operating partners support founding teams at every stage of company-building across executive talent, design, communications, and marketing. GV is a non-strategic venture capital firm that invests independently from its sole limited partner, Alphabet. We connect startups with Google and Alphabet companies, providing unique access to the world’s best technology and talent.
GV has 400 active portfolio companies spanning North America, Europe, and Israel. Our portfolio includes Lightmatter, Stripe, Treeline Biosciences, Vercel, and Wonder, with notable exits including Uber, Nest, Slack, GitLab, Duo Security, Flatiron Health, Lemonade, and One Medical. The firm is headquartered in the San Francisco Bay Area, with offices in Cambridge, New York, and London.